9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 126

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Phase II: Progression free survival measured as time from randomization to first observation of objective disease relapse or progression,  Phase III: Overall Survival defined as time from randomization to the date of death from any cause,  Number and severity of adverse events, Overall Survival

Interventions: Cisplatin, Pemetrexed

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 2020

Completion Date: February 2021

Last  Posted Date: July 15, 2019

Location: Tom Baker Cancer Centre, Calgary, Alberta, Canada

Website Link: https://ClinicalTrials.gov/show/NCT02784171

Was this article helpful?
Dislike 0